Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
2024
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
2024
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
2015
Drugs and The Respiratory System
2017
Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
2016
ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
2016
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
2016
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
